What is AFINITOR 10mg
AFINITOR is the brand name for oral **Everolimus**, a targeted cancer therapy belonging to the **mTOR (mammalian target of rapamycin) inhibitor** class. Each tablet contains 10 mg of the active ingredient, provided in a pack of 30 tablets (3 blisters of 10 tablets each). Over time, the active ingredient may be available in generic forms.
- Oncology uses: Advanced renal cell carcinoma, hormone receptor‑positive, HER2‑negative breast cancer (postmenopausal), unresectable or metastatic neuroendocrine tumors, renal angiomyolipoma, and SEGA in tuberous sclerosis complex :contentReference[oaicite:1]{index=1}.
- Immunosuppressive use: In transplant medicine under names such as Zortress or Certican to prevent organ rejection :contentReference[oaicite:2]{index=2}.
- Essential medicine: Recognised by WHO as vital for basic healthcare :contentReference[oaicite:3]{index=3}.
By inhibiting mTOR signaling, AFINITOR blocks tumor cell growth and angiogenesis. Its role in immunosuppression and potential in drug-eluting stents also underscores its widely diverse clinical applications.
How to use AFINITOR 10mg
Administration should follow the prescribing oncologist’s instructions. General guidelines:
- Schedule: One tablet (10 mg) orally once daily, at the same time each day — continue until disease progression or intolerable toxicity :contentReference[oaicite:4]{index=4}.
- Method: Swallow whole with a full glass of water; do not chew or split :contentReference[oaicite:5]{index=5}.
- Food: Can be taken with or without food, but maintain consistency :contentReference[oaicite:6]{index=6}.
- Missed dose: If <6 hours late, take immediately; if >6 hours, skip and resume next day. Do not double up :contentReference[oaicite:7]{index=7}.
- Monitoring: Regular check-ups—CBC, liver and kidney function, lipid panel, and glucose—are recommended, especially early in treatment :contentReference[oaicite:8]{index=8}.
- Avoid grapefruit: Grapefruit and juice should be avoided as they can raise Everolimus levels :contentReference[oaicite:9]{index=9}.
Strict consistency in dosing and vigilant follow-up helps maximize efficacy and minimize toxicity.
Mode of Action AFINITOR 10mg
Everolimus exerts its primary action by inhibiting the protein kinase **mTORC1**, a central regulator of cell growth, proliferation, metabolism, and angiogenesis.
- FKBP12 binding: Everolimus binds to FKBP12 protein, and this complex specifically inhibits mTORC1, blocking progression from G1 to S phase in the cell cycle :contentReference[oaicite:10]{index=10}.
- Antiproliferative effects: Tumor cells stop multiplying; efficacy observed in cancers and in reducing angiogenesis :contentReference[oaicite:11]{index=11}.
- Antiangiogenesis: Suppresses VEGF expression and vessel formation, limiting tumor nutrient supply :contentReference[oaicite:12]{index=12}.
- Selective targeting: Preferentially inhibits mTORC1 over mTORC2, reducing side effects like glucose intolerance :contentReference[oaicite:13]{index=13}.
- Immunomodulatory action: Dampens immune function, beneficial in transplant but requiring infection vigilance :contentReference[oaicite:14]{index=14}.
This multifunctional mechanism—both antiproliferative and antiangiogenic—enables AFINITOR to be effective in diverse oncologic and immunologic settings.
AFINITOR 10mg Interactions AFINITOR 10mg
Everolimus is primarily metabolized by **CYP3A4** and is also a substrate of **P‑glycoprotein (P‑gp)**. Numerous clinically significant drug interactions can alter blood levels of AFINITOR:
- ↑ Drug levels (CYP3A4/P‑gp inhibitors): Ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice—can potentiate toxicity :contentReference[oaicite:15]{index=15}.
- ↓ Drug levels (CYP3A4/P‑gp inducers): Rifampin, phenytoin, carbamazepine, St. John’s Wort—may reduce therapeutic effect :contentReference[oaicite:16]{index=16}.
- ACE Inhibitors: Combined use may increase angioedema risk :contentReference[oaicite:17]{index=17}.
- Corticosteroids & immunosuppressants: Combined use requires monitoring for infections and drug levels :contentReference[oaicite:18]{index=18}.
- Vaccines: Avoid live vaccines to reduce infection risk :contentReference[oaicite:19]{index=19}.
- Nephrotoxic drugs: NSAIDs and certain antibiotics may add to renal risk :contentReference[oaicite:20]{index=20}.
Before starting AFINITOR, share a full list of medications, including herbal supplements and over‑the‑counter drugs, to help anticipate and manage interactions effectively.
Dosage of AFINITOR 10mg
Dosing depends on condition and patient characteristics. Typical regimens include:
- Adult cancer indications (RCC, NET, breast cancer, angiomyolipoma): 10 mg orally once daily until therapy stops :contentReference[oaicite:21]{index=21}.
- TSC‑associated SEGA in pediatrics: 2.5 to 7.5 mg once daily, based on body surface area and trough levels :contentReference[oaicite:22]{index=22}.
- TSC‑associated seizures: AFINITOR DISPERZ (suspension form), 5 mg/m² once daily :contentReference[oaicite:23]{index=23}.
- Hepatic impairment or drug interactions: Dose reduction to 5 mg (or even 2.5 mg) may be necessary :contentReference[oaicite:24]{index=24}.
- Adjustments: Based on lab results, side effects like pneumonitis or myelosuppression, and drug interactions :contentReference[oaicite:25]{index=25}.
- Monitoring: Therapeutic drug monitoring (trough levels 5–15 ng/mL) is recommended, especially in pediatrics or with interacting drugs :contentReference[oaicite:26]{index=26}.
Any dose changes—reductions or interruptions—should be physician-supervised based on side effects or lab results.
Possible side effects of AFINITOR 10mg
AFINITOR has both common and potentially serious adverse effects. Monitoring and timely management are critical.
Common side effects (≥30% incidence):
- Mouth ulcers/stomatitis (44–78% incidence) :contentReference[oaicite:27]{index=27}.
- Fatigue, weakness, loss of appetite :contentReference[oaicite:28]{index=28}.
- Rash, dry or itchy skin (up to 59%) :contentReference[oaicite:29]{index=29}.
- Gastrointestinal upset: diarrhea, constipation, nausea/vomiting :contentReference[oaicite:30]{index=30}.
- Infections (including serious types in ~10%) :contentReference[oaicite:31]{index=31}.
- Edema (hands, feet, face), abnormal taste, mouth/throat pain :contentReference[oaicite:32]{index=32}.
- Metabolic changes: hyperglycemia and hyperlipidemia (up to 75–86%) :contentReference[oaicite:33]{index=33}.
Serious effects (≤10% incidence but medically significant):
- Non‑infectious pneumonitis (19% incidence; Grade 3/4 in some) :contentReference[oaicite:34]{index=34}.
- Myelosuppression: anemia, neutropenia, thrombocytopenia (up to Grade 3/4) :contentReference[oaicite:35]{index=35}.
- Renal impairment, including acute failure :contentReference[oaicite:36]{index=36}.
- Angioedema—especially with ACE inhibitors :contentReference[oaicite:37]{index=37}.
- Severe infection risk, including opportunistic infections :contentReference[oaicite:38]{index=38}.
Patients should promptly report breathing difficulties, persistent infections, mouth pain, unexpected bleeding, or metabolic abnormalities. Dose modifications or discontinuation may be required depending on severity.
AFINITOR 10mg Contraindications AFINITOR 10mg
AFINITOR is contraindicated in certain circumstances to avoid life-threatening consequences:
- Hypersensitivity: Allergy to everolimus, other rapalogs (e.g., sirolimus), or formulation excipients :contentReference[oaicite:39]{index=39}.
- Severe hepatic impairment: Caution or avoid unless under specialist supervision :contentReference[oaicite:40]{index=40}.
- Pregnancy/breastfeeding: Can cause fetal harm; effective contraception is essential during therapy and for weeks after discontinuation :contentReference[oaicite:41]{index=41}.
- Untreated infections: Active serious infections must be controlled before starting :contentReference[oaicite:42]{index=42}.
- Live vaccine contraindication: Avoid during and shortly after treatment due to immunosuppression :contentReference[oaicite:43]{index=43}.
- Pediatrics (under 1 year or BSA < 0.58 m²): Contraindicated for SEGA :contentReference[oaicite:44]{index=44}.
A full evaluation must be done before initiating therapy to assess risks from comorbid conditions, other drugs, and organ function.
Storage of AFINITOR 10mg
Maintaining the medication’s integrity requires proper storage:
- Temperature: Store at 20–25 °C (68–77 °F), with excursions permitted between 15–30 °C (59–86 °F) :contentReference[oaicite:45]{index=45}.
- Packaging: Keep tablets in original blister pack until use; protect from light and moisture :contentReference[oaicite:46]{index=46}.
- Discarding: Do not use after expiry date; properly dispose of used/blistered tablets in accordance with local guidelines :contentReference[oaicite:47]{index=47}.
- Safety: Keep out of reach of children and pets :contentReference[oaicite:48]{index=48}.
Following these guidelines helps preserve therapeutic efficacy and patient safety.
AFINITOR 10mg features an exceptional active ingredient renowned for its potent effects, comprising Everolimus. This powerful formulation provides a superior solution for addressing diverse health concerns. With 10mg/Tablet concentration and an easily manageable Tablets, it remains a preferred option for countless individuals seeking effective treatment.
Introduction
All you need to know about AFINITOR 10mg .
Welcome to Dwaey, specifically on AFINITOR 10mg page.
This medicine contains an important and useful components, as it consists of Everolimus.
AFINITOR 10mg is available in the market in concentration 10mg/Tablet and in the form of Tablets.
NOVARTIS PHARMA AG is the producer of AFINITOR 10mg and it is imported from SWITZERLAND,
The most popular alternatives of AFINITOR 10mg are listed downward .
-
Active Substance
-
Size
-
Indications
-
Type
-
Company
Frequently Asked Questions
AFINITOR 10mg should be stored according to the instructions provided by NOVARTIS PHARMA AG.
In general, it is recommended to store AFINITOR 10mg in a cool, dry place, away from direct sunlight
and out of the reach of children.
The duration of treatment with AFINITOR 10mg may vary depending on the condition being treated
and the guidance of your healthcare provider. It is important to follow the prescribed treatment
plan and continue taking AFINITOR 10mg for the recommended duration, even if your symptoms improve.
If you have any concerns or questions about the duration of treatment, consult your healthcare provider.
It is important to check with your healthcare provider or read the medication label for specific
instructions regarding alcohol consumption while taking AFINITOR 10mg. Some medications, including
AFINITOR 10mg, may have interactions with alcohol that can reduce effectiveness, increase side
effects, or pose other risks to your health. It is best to follow the guidance provided by your
healthcare professional.
If you miss a dose of AFINITOR 10mg, take it as soon as you remember. However, if it is close
to the time for your next scheduled dose, skip the missed dose and continue with your regular dosing
schedule. Do not take a double dose to make up for a missed one unless advised by your healthcare provider.
No, do not stop taking AFINITOR 10mg without consulting your healthcare provider, even if your
symptoms improve. It is important to complete the full course of treatment as prescribed. Stopping
the medication prematurely may lead to a relapse or incomplete resolution of the condition. If you
have concerns about the duration of treatment, consult your healthcare provider for guidance.
It is important to consult your healthcare provider before taking AFINITOR 10mg if you are
pregnant or breastfeeding. They will be able to assess the potential risks and benefits based on your
specific situation. Please note that the safety and suitability of AFINITOR 10mg during pregnancy
or breastfeeding may depend on the active substance [Active Substance], concentration 10mg/Tablet,
and the specific recommendations of NOVARTIS PHARMA AG.
The effects of AFINITOR 10mg on your ability to drive or operate machinery can vary depending on
the active substance [Active Substance], concentration 10mg/Tablet, and individual factors.
Some medications may cause drowsiness, dizziness, or other side effects that can impair your judgment
or coordination. It is important to read the medication label or consult your healthcare provider to
understand any potential effects on your ability to perform tasks that require alertness.
The instructions for taking AFINITOR 10mg with or without food may vary depending on the medication
and the recommendations of NOVARTIS PHARMA AG. Some medications may be more effective when taken with
food to enhance absorption or reduce stomach irritation, while others may need to be taken on an empty
stomach for optimal absorption. Read the medication label or consult your healthcare provider for specific instructions.
The use of AFINITOR 10mg in children or elderly individuals may depend on various factors, including
the specific medication, type Tablets, and the recommendations of NOVARTIS PHARMA AG. Some
medications may have specific dosing instructions or precautions for these age groups. Consult your
healthcare provider or read the medication label for information regarding the safe and appropriate use
of AFINITOR 10mg in children or elderly individuals.
Dwaey
All medical information published on the Dwaey website aims to increase medical awareness and health education among users. However, it is not a substitute for professional medical advice. Always consult with a specialist doctor. We strongly advise against using any information or medicine found on the site without referring to your healthcare provider.
Related Products
0 Comments